Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • data transparency

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

    The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

    The neurodegenerative disease affects almost seven million people in the US

    Biogen Idec building

    Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

    The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

    The neurodegenerative disorder affects an estimated 6.9 million people in Europe

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug approved by MHRA but not recommended by NICE

    The health technology assessment agency outlined that the drug's benefits are “too small” to justify its costs

    - PMLiVE

    Eisai and SEED enter molecular glue degrader partnership worth up to $1.5bn

    The companies are aiming to develop candidates for multiple neurodegeneration and oncology targets

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

    Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

    Biogen Idec building

    Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer’s drug

    The Leqembi SC autoinjector could reduce the need for hospital visits and nursing care compared to IV administration

    - PMLiVE

    Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer’s treatment

    AD is the most common form of dementia, which affects around 55 million people globally

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links